| Dr Abbey Merryman, MD | |
|
200 Hawkins Dr, Dept Of Obstetrics And Gynecology, Iowa City, IA 52242-1009 | |
| (319) 353-8481 | |
| (319) 384-8620 |
| Full Name | Dr Abbey Merryman |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 14 Years |
| Location | 200 Hawkins Dr, Iowa City, Iowa |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487972451 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 41898 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Iowa Hospital & Clinics | Iowa city, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| State University Of Iowa | 7618884230 | 1476 |
News Archive
The ventilator, developed by researchers from the Medical Robotics Research Group of the University of Málaga in a record time of 20 days to strengthen health care response to COVID-19, is already being manufactured, after receiving authorization from the Spanish Agency of Medicines and Medical Devices upon fulfilling all requirements for its approval.
Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.
People with chronic illnesses can experience great difficulties in prison, but people such as drug addicts and the homeless may find their healthcare improves, according to a study in the latest Journal of Advanced Nursing.
Radioactive iodine may be selectively used for the treatment of intermediate-risk papillary thyroid cancer in patients who are aged over 45 years with tumors smaller than 4 cm that are confined to the thyroid gland, say US scientists.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that it has entered into a research collaboration with Mirna Therapeutics (Austin, TX), to determine the utility of combining RXi's proprietary rxRNA™ technology with Mirna's microRNA mimics as potential therapeutics in oncology. The parties will each contribute technology and resources to the collaboration to generate and evaluate novel microRNA compounds.
› Verified 3 days ago
| Entity Name | State University Of Iowa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477554814 PECOS PAC ID: 7618884230 Enrollment ID: O20031107000060 |
News Archive
The ventilator, developed by researchers from the Medical Robotics Research Group of the University of Málaga in a record time of 20 days to strengthen health care response to COVID-19, is already being manufactured, after receiving authorization from the Spanish Agency of Medicines and Medical Devices upon fulfilling all requirements for its approval.
Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.
People with chronic illnesses can experience great difficulties in prison, but people such as drug addicts and the homeless may find their healthcare improves, according to a study in the latest Journal of Advanced Nursing.
Radioactive iodine may be selectively used for the treatment of intermediate-risk papillary thyroid cancer in patients who are aged over 45 years with tumors smaller than 4 cm that are confined to the thyroid gland, say US scientists.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that it has entered into a research collaboration with Mirna Therapeutics (Austin, TX), to determine the utility of combining RXi's proprietary rxRNA™ technology with Mirna's microRNA mimics as potential therapeutics in oncology. The parties will each contribute technology and resources to the collaboration to generate and evaluate novel microRNA compounds.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Abbey Merryman, MD 200 Hawkins Dr, Dept Of Obstetrics And Gynecology, Iowa City, IA 52242-1009 Ph: (319) 353-8481 | Dr Abbey Merryman, MD 200 Hawkins Dr, Dept Of Obstetrics And Gynecology, Iowa City, IA 52242-1009 Ph: (319) 353-8481 |
News Archive
The ventilator, developed by researchers from the Medical Robotics Research Group of the University of Málaga in a record time of 20 days to strengthen health care response to COVID-19, is already being manufactured, after receiving authorization from the Spanish Agency of Medicines and Medical Devices upon fulfilling all requirements for its approval.
Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.
People with chronic illnesses can experience great difficulties in prison, but people such as drug addicts and the homeless may find their healthcare improves, according to a study in the latest Journal of Advanced Nursing.
Radioactive iodine may be selectively used for the treatment of intermediate-risk papillary thyroid cancer in patients who are aged over 45 years with tumors smaller than 4 cm that are confined to the thyroid gland, say US scientists.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that it has entered into a research collaboration with Mirna Therapeutics (Austin, TX), to determine the utility of combining RXi's proprietary rxRNA™ technology with Mirna's microRNA mimics as potential therapeutics in oncology. The parties will each contribute technology and resources to the collaboration to generate and evaluate novel microRNA compounds.
› Verified 3 days ago
Sofia Gabrilovich, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 813-416-4223 | |
Ashley Kaiser, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 200 Hawkins Dr, Dept Of Obgyn, Iowa City, IA 52242 Phone: 319-356-2294 Fax: 319-356-7533 | |
Barrie Anderson, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 200 Hawkins Dr, University Of Iowa Hospitals & Clinics, Iowa City, IA 52242 Phone: 319-356-2015 Fax: 319-353-8363 | |
Dr. Margaret Long Foster, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 200 Hawkins Dr Dept Obgyn, Iowa City, IA 52242 Phone: 319-356-2294 Fax: 319-384-8620 | |
Dr. Garrett K. Lam, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-356-1616 Fax: 319-356-2133 | |
Dr. Megan Elaine Mcdonald, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-356-2015 Fax: 319-353-8363 | |
Dr. Christopher D Clark, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-356-2294 Fax: 319-384-9693 |